Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58
Aims Dapagliflozin reduced the risk of the composite of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes mellitus in DECLARE‐TIMI 58. We hypothesized that baseline N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) and high‐sensitivity troponin...
Gespeichert in:
| Veröffentlicht in: | European journal of heart failure 2021-06, Vol.23 (6), p.1026-1036 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1036 |
|---|---|
| container_issue | 6 |
| container_start_page | 1026 |
| container_title | European journal of heart failure |
| container_volume | 23 |
| creator | Zelniker, Thomas A. Morrow, David A. Mosenzon, Ofri Goodrich, Erica L. Jarolim, Petr Murphy, Sabina A. Bhatt, Deepak L. Leiter, Lawrence A. McGuire, Darren K. Wilding, John Bode, Christoph Lewis, Basil S. Gause‐Nilsson, Ingrid Langkilde, Anna Maria Fredriksson, Martin Raz, Itamar Sabatine, Marc S. Wiviott, Stephen D. |
| description | Aims
Dapagliflozin reduced the risk of the composite of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes mellitus in DECLARE‐TIMI 58. We hypothesized that baseline N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) and high‐sensitivity troponin T (hsTnT) levels would help identify patients who are at higher baseline risk and we describe the treatment effects of dapagliflozin in patients according to their baseline NT‐proBNP and hsTnT levels.
Methods and results
This was a pre‐specified biomarker study from DECLARE‐TIMI 58, a randomized, double‐blind, placebo‐controlled CV outcomes trial of dapagliflozin. Baseline NT‐proBNP and hsTnT levels were measured in the TIMI Clinical Trials Laboratory in 14 565 patients. Among the included patients, 9143 patients (62.8%) were male, 1464 (10.1%) had a history of heart failure and the mean age was 63.9 years. The median baseline NT‐proBNP and hsTnT levels were 75 pg/mL [interquartile range (IQR) 35–165] and 10.2 pg/mL (IQR 6.9–15.5), respectively. Patients with higher NT‐proBNP and hsTnT quartiles had higher rates of CV death/HHF (Q4 vs. Q1: NT‐proBNP: 4‐year Kaplan–Meier event rates 13.7% vs. 1.0%; hsTnT: 11.8% vs. 1.4%; P‐trend |
| doi_str_mv | 10.1002/ejhf.2073 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2466772027</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2466772027</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3603-1d24ef721892c01208c7d1372fcf57d7944770d2b5e4d473f9419f4d4414d4aa3</originalsourceid><addsrcrecordid>eNp1kUFu1DAYhS0EoqWw4ALIS1iktR1PnCyr6ZQOGoRUlXXk2L-JiycOtsNoWPUISNyKY_QkOJ3Cjo399PTps-SH0GtKTikh7Axue3PKiCifoGNai6YgNedPcy7rumhqzo7QixhvCaEi48_RUVmyquF1dYx-X4OTyfoh9nbEHaQdwIA7GcHZAbCSQVupcGf9VoavECKWgz7U_ruManIyYA0y9dgH3Ps42iSd_fHgxGbuQIaEjbRuCoB3NpOzYg5-Sjh6baft_d2vL25SPuYn_f3dzxTkEEcfEgTMsB1629mUZamHIMd9bvDFark5v15l-Gb9cY0X9Uv0zEgX4dXjfYI-X65ullfF5tP79fJ8U6iyImVBNeNgBKN1wxShjNRKaFoKZpRZCC0azoUgmnUL4JqL0jScNiZHTvMhZXmC3h68Y_DfJoip3dqowDk5gJ9iy3hVCcEIExl9d0BV8DEGMO0YbP7IfUtJO0_XztO183SZffOonbot6H_k360ycHYAdtbB_v-mdvXh6vJB-QemeaoO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2466772027</pqid></control><display><type>article</type><title>Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58</title><source>MEDLINE</source><source>Wiley Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><creator>Zelniker, Thomas A. ; Morrow, David A. ; Mosenzon, Ofri ; Goodrich, Erica L. ; Jarolim, Petr ; Murphy, Sabina A. ; Bhatt, Deepak L. ; Leiter, Lawrence A. ; McGuire, Darren K. ; Wilding, John ; Bode, Christoph ; Lewis, Basil S. ; Gause‐Nilsson, Ingrid ; Langkilde, Anna Maria ; Fredriksson, Martin ; Raz, Itamar ; Sabatine, Marc S. ; Wiviott, Stephen D.</creator><creatorcontrib>Zelniker, Thomas A. ; Morrow, David A. ; Mosenzon, Ofri ; Goodrich, Erica L. ; Jarolim, Petr ; Murphy, Sabina A. ; Bhatt, Deepak L. ; Leiter, Lawrence A. ; McGuire, Darren K. ; Wilding, John ; Bode, Christoph ; Lewis, Basil S. ; Gause‐Nilsson, Ingrid ; Langkilde, Anna Maria ; Fredriksson, Martin ; Raz, Itamar ; Sabatine, Marc S. ; Wiviott, Stephen D.</creatorcontrib><description>Aims
Dapagliflozin reduced the risk of the composite of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes mellitus in DECLARE‐TIMI 58. We hypothesized that baseline N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) and high‐sensitivity troponin T (hsTnT) levels would help identify patients who are at higher baseline risk and we describe the treatment effects of dapagliflozin in patients according to their baseline NT‐proBNP and hsTnT levels.
Methods and results
This was a pre‐specified biomarker study from DECLARE‐TIMI 58, a randomized, double‐blind, placebo‐controlled CV outcomes trial of dapagliflozin. Baseline NT‐proBNP and hsTnT levels were measured in the TIMI Clinical Trials Laboratory in 14 565 patients. Among the included patients, 9143 patients (62.8%) were male, 1464 (10.1%) had a history of heart failure and the mean age was 63.9 years. The median baseline NT‐proBNP and hsTnT levels were 75 pg/mL [interquartile range (IQR) 35–165] and 10.2 pg/mL (IQR 6.9–15.5), respectively. Patients with higher NT‐proBNP and hsTnT quartiles had higher rates of CV death/HHF (Q4 vs. Q1: NT‐proBNP: 4‐year Kaplan–Meier event rates 13.7% vs. 1.0%; hsTnT: 11.8% vs. 1.4%; P‐trend <0.001). Dapagliflozin consistently reduced the relative risk of CV death/HHF regardless of baseline NT‐proBNP (P‐interaction 0.72) or hsTnT quartiles (P‐interaction 0.93). Given their higher baseline risk, patients with NT‐proBNP and/or hsTnT levels above the median derived larger absolute risk reductions with dapagliflozin (NT‐proBNP 1.9% vs. 0%, P‐interaction 0.010; hsTnT 1.8% vs. 0.1%, P‐interaction 0.026).
Conclusion
Patients with type 2 diabetes mellitus and higher NT‐proBNP or hsTnT levels are at increased risk of CV death and HHF. Dapagliflozin reduced the relative risk of CV death/HHF irrespective of NT‐proBNP and hsTnT levels, with greater absolute risk reductions seen in patients with higher baseline biomarker levels.</description><identifier>ISSN: 1388-9842</identifier><identifier>EISSN: 1879-0844</identifier><identifier>DOI: 10.1002/ejhf.2073</identifier><identifier>PMID: 33269486</identifier><language>eng</language><publisher>Oxford, UK: John Wiley & Sons, Ltd</publisher><subject>Biomarker ; Biomarkers ; Dapagliflozin ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - epidemiology ; Female ; Glucose ; Heart Failure - drug therapy ; Heart Failure - epidemiology ; High‐sensitivity troponin T ; Hospitalization ; Humans ; Male ; Middle Aged ; Natriuretic Peptide, Brain ; NT‐proBNP ; Peptide Fragments ; Sodium ; Sodium-Glucose Transporter 2 Inhibitors ; Sodium–glucose co‐transporter 2 inhibitors ; Symporters ; Type 2 diabetes mellitus</subject><ispartof>European journal of heart failure, 2021-06, Vol.23 (6), p.1026-1036</ispartof><rights>2020 European Society of Cardiology</rights><rights>2020 European Society of Cardiology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3603-1d24ef721892c01208c7d1372fcf57d7944770d2b5e4d473f9419f4d4414d4aa3</citedby><cites>FETCH-LOGICAL-c3603-1d24ef721892c01208c7d1372fcf57d7944770d2b5e4d473f9419f4d4414d4aa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fejhf.2073$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fejhf.2073$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,1432,27923,27924,45573,45574,46408,46832</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33269486$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zelniker, Thomas A.</creatorcontrib><creatorcontrib>Morrow, David A.</creatorcontrib><creatorcontrib>Mosenzon, Ofri</creatorcontrib><creatorcontrib>Goodrich, Erica L.</creatorcontrib><creatorcontrib>Jarolim, Petr</creatorcontrib><creatorcontrib>Murphy, Sabina A.</creatorcontrib><creatorcontrib>Bhatt, Deepak L.</creatorcontrib><creatorcontrib>Leiter, Lawrence A.</creatorcontrib><creatorcontrib>McGuire, Darren K.</creatorcontrib><creatorcontrib>Wilding, John</creatorcontrib><creatorcontrib>Bode, Christoph</creatorcontrib><creatorcontrib>Lewis, Basil S.</creatorcontrib><creatorcontrib>Gause‐Nilsson, Ingrid</creatorcontrib><creatorcontrib>Langkilde, Anna Maria</creatorcontrib><creatorcontrib>Fredriksson, Martin</creatorcontrib><creatorcontrib>Raz, Itamar</creatorcontrib><creatorcontrib>Sabatine, Marc S.</creatorcontrib><creatorcontrib>Wiviott, Stephen D.</creatorcontrib><title>Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58</title><title>European journal of heart failure</title><addtitle>Eur J Heart Fail</addtitle><description>Aims
Dapagliflozin reduced the risk of the composite of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes mellitus in DECLARE‐TIMI 58. We hypothesized that baseline N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) and high‐sensitivity troponin T (hsTnT) levels would help identify patients who are at higher baseline risk and we describe the treatment effects of dapagliflozin in patients according to their baseline NT‐proBNP and hsTnT levels.
Methods and results
This was a pre‐specified biomarker study from DECLARE‐TIMI 58, a randomized, double‐blind, placebo‐controlled CV outcomes trial of dapagliflozin. Baseline NT‐proBNP and hsTnT levels were measured in the TIMI Clinical Trials Laboratory in 14 565 patients. Among the included patients, 9143 patients (62.8%) were male, 1464 (10.1%) had a history of heart failure and the mean age was 63.9 years. The median baseline NT‐proBNP and hsTnT levels were 75 pg/mL [interquartile range (IQR) 35–165] and 10.2 pg/mL (IQR 6.9–15.5), respectively. Patients with higher NT‐proBNP and hsTnT quartiles had higher rates of CV death/HHF (Q4 vs. Q1: NT‐proBNP: 4‐year Kaplan–Meier event rates 13.7% vs. 1.0%; hsTnT: 11.8% vs. 1.4%; P‐trend <0.001). Dapagliflozin consistently reduced the relative risk of CV death/HHF regardless of baseline NT‐proBNP (P‐interaction 0.72) or hsTnT quartiles (P‐interaction 0.93). Given their higher baseline risk, patients with NT‐proBNP and/or hsTnT levels above the median derived larger absolute risk reductions with dapagliflozin (NT‐proBNP 1.9% vs. 0%, P‐interaction 0.010; hsTnT 1.8% vs. 0.1%, P‐interaction 0.026).
Conclusion
Patients with type 2 diabetes mellitus and higher NT‐proBNP or hsTnT levels are at increased risk of CV death and HHF. Dapagliflozin reduced the relative risk of CV death/HHF irrespective of NT‐proBNP and hsTnT levels, with greater absolute risk reductions seen in patients with higher baseline biomarker levels.</description><subject>Biomarker</subject><subject>Biomarkers</subject><subject>Dapagliflozin</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - epidemiology</subject><subject>Female</subject><subject>Glucose</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - epidemiology</subject><subject>High‐sensitivity troponin T</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Natriuretic Peptide, Brain</subject><subject>NT‐proBNP</subject><subject>Peptide Fragments</subject><subject>Sodium</subject><subject>Sodium-Glucose Transporter 2 Inhibitors</subject><subject>Sodium–glucose co‐transporter 2 inhibitors</subject><subject>Symporters</subject><subject>Type 2 diabetes mellitus</subject><issn>1388-9842</issn><issn>1879-0844</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUFu1DAYhS0EoqWw4ALIS1iktR1PnCyr6ZQOGoRUlXXk2L-JiycOtsNoWPUISNyKY_QkOJ3Cjo399PTps-SH0GtKTikh7Axue3PKiCifoGNai6YgNedPcy7rumhqzo7QixhvCaEi48_RUVmyquF1dYx-X4OTyfoh9nbEHaQdwIA7GcHZAbCSQVupcGf9VoavECKWgz7U_ruManIyYA0y9dgH3Ps42iSd_fHgxGbuQIaEjbRuCoB3NpOzYg5-Sjh6baft_d2vL25SPuYn_f3dzxTkEEcfEgTMsB1629mUZamHIMd9bvDFark5v15l-Gb9cY0X9Uv0zEgX4dXjfYI-X65ullfF5tP79fJ8U6iyImVBNeNgBKN1wxShjNRKaFoKZpRZCC0azoUgmnUL4JqL0jScNiZHTvMhZXmC3h68Y_DfJoip3dqowDk5gJ9iy3hVCcEIExl9d0BV8DEGMO0YbP7IfUtJO0_XztO183SZffOonbot6H_k360ycHYAdtbB_v-mdvXh6vJB-QemeaoO</recordid><startdate>202106</startdate><enddate>202106</enddate><creator>Zelniker, Thomas A.</creator><creator>Morrow, David A.</creator><creator>Mosenzon, Ofri</creator><creator>Goodrich, Erica L.</creator><creator>Jarolim, Petr</creator><creator>Murphy, Sabina A.</creator><creator>Bhatt, Deepak L.</creator><creator>Leiter, Lawrence A.</creator><creator>McGuire, Darren K.</creator><creator>Wilding, John</creator><creator>Bode, Christoph</creator><creator>Lewis, Basil S.</creator><creator>Gause‐Nilsson, Ingrid</creator><creator>Langkilde, Anna Maria</creator><creator>Fredriksson, Martin</creator><creator>Raz, Itamar</creator><creator>Sabatine, Marc S.</creator><creator>Wiviott, Stephen D.</creator><general>John Wiley & Sons, Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202106</creationdate><title>Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58</title><author>Zelniker, Thomas A. ; Morrow, David A. ; Mosenzon, Ofri ; Goodrich, Erica L. ; Jarolim, Petr ; Murphy, Sabina A. ; Bhatt, Deepak L. ; Leiter, Lawrence A. ; McGuire, Darren K. ; Wilding, John ; Bode, Christoph ; Lewis, Basil S. ; Gause‐Nilsson, Ingrid ; Langkilde, Anna Maria ; Fredriksson, Martin ; Raz, Itamar ; Sabatine, Marc S. ; Wiviott, Stephen D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3603-1d24ef721892c01208c7d1372fcf57d7944770d2b5e4d473f9419f4d4414d4aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biomarker</topic><topic>Biomarkers</topic><topic>Dapagliflozin</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - epidemiology</topic><topic>Female</topic><topic>Glucose</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - epidemiology</topic><topic>High‐sensitivity troponin T</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Natriuretic Peptide, Brain</topic><topic>NT‐proBNP</topic><topic>Peptide Fragments</topic><topic>Sodium</topic><topic>Sodium-Glucose Transporter 2 Inhibitors</topic><topic>Sodium–glucose co‐transporter 2 inhibitors</topic><topic>Symporters</topic><topic>Type 2 diabetes mellitus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zelniker, Thomas A.</creatorcontrib><creatorcontrib>Morrow, David A.</creatorcontrib><creatorcontrib>Mosenzon, Ofri</creatorcontrib><creatorcontrib>Goodrich, Erica L.</creatorcontrib><creatorcontrib>Jarolim, Petr</creatorcontrib><creatorcontrib>Murphy, Sabina A.</creatorcontrib><creatorcontrib>Bhatt, Deepak L.</creatorcontrib><creatorcontrib>Leiter, Lawrence A.</creatorcontrib><creatorcontrib>McGuire, Darren K.</creatorcontrib><creatorcontrib>Wilding, John</creatorcontrib><creatorcontrib>Bode, Christoph</creatorcontrib><creatorcontrib>Lewis, Basil S.</creatorcontrib><creatorcontrib>Gause‐Nilsson, Ingrid</creatorcontrib><creatorcontrib>Langkilde, Anna Maria</creatorcontrib><creatorcontrib>Fredriksson, Martin</creatorcontrib><creatorcontrib>Raz, Itamar</creatorcontrib><creatorcontrib>Sabatine, Marc S.</creatorcontrib><creatorcontrib>Wiviott, Stephen D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of heart failure</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zelniker, Thomas A.</au><au>Morrow, David A.</au><au>Mosenzon, Ofri</au><au>Goodrich, Erica L.</au><au>Jarolim, Petr</au><au>Murphy, Sabina A.</au><au>Bhatt, Deepak L.</au><au>Leiter, Lawrence A.</au><au>McGuire, Darren K.</au><au>Wilding, John</au><au>Bode, Christoph</au><au>Lewis, Basil S.</au><au>Gause‐Nilsson, Ingrid</au><au>Langkilde, Anna Maria</au><au>Fredriksson, Martin</au><au>Raz, Itamar</au><au>Sabatine, Marc S.</au><au>Wiviott, Stephen D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58</atitle><jtitle>European journal of heart failure</jtitle><addtitle>Eur J Heart Fail</addtitle><date>2021-06</date><risdate>2021</risdate><volume>23</volume><issue>6</issue><spage>1026</spage><epage>1036</epage><pages>1026-1036</pages><issn>1388-9842</issn><eissn>1879-0844</eissn><abstract>Aims
Dapagliflozin reduced the risk of the composite of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes mellitus in DECLARE‐TIMI 58. We hypothesized that baseline N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) and high‐sensitivity troponin T (hsTnT) levels would help identify patients who are at higher baseline risk and we describe the treatment effects of dapagliflozin in patients according to their baseline NT‐proBNP and hsTnT levels.
Methods and results
This was a pre‐specified biomarker study from DECLARE‐TIMI 58, a randomized, double‐blind, placebo‐controlled CV outcomes trial of dapagliflozin. Baseline NT‐proBNP and hsTnT levels were measured in the TIMI Clinical Trials Laboratory in 14 565 patients. Among the included patients, 9143 patients (62.8%) were male, 1464 (10.1%) had a history of heart failure and the mean age was 63.9 years. The median baseline NT‐proBNP and hsTnT levels were 75 pg/mL [interquartile range (IQR) 35–165] and 10.2 pg/mL (IQR 6.9–15.5), respectively. Patients with higher NT‐proBNP and hsTnT quartiles had higher rates of CV death/HHF (Q4 vs. Q1: NT‐proBNP: 4‐year Kaplan–Meier event rates 13.7% vs. 1.0%; hsTnT: 11.8% vs. 1.4%; P‐trend <0.001). Dapagliflozin consistently reduced the relative risk of CV death/HHF regardless of baseline NT‐proBNP (P‐interaction 0.72) or hsTnT quartiles (P‐interaction 0.93). Given their higher baseline risk, patients with NT‐proBNP and/or hsTnT levels above the median derived larger absolute risk reductions with dapagliflozin (NT‐proBNP 1.9% vs. 0%, P‐interaction 0.010; hsTnT 1.8% vs. 0.1%, P‐interaction 0.026).
Conclusion
Patients with type 2 diabetes mellitus and higher NT‐proBNP or hsTnT levels are at increased risk of CV death and HHF. Dapagliflozin reduced the relative risk of CV death/HHF irrespective of NT‐proBNP and hsTnT levels, with greater absolute risk reductions seen in patients with higher baseline biomarker levels.</abstract><cop>Oxford, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>33269486</pmid><doi>10.1002/ejhf.2073</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1388-9842 |
| ispartof | European journal of heart failure, 2021-06, Vol.23 (6), p.1026-1036 |
| issn | 1388-9842 1879-0844 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2466772027 |
| source | MEDLINE; Wiley Free Content; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals |
| subjects | Biomarker Biomarkers Dapagliflozin Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - epidemiology Female Glucose Heart Failure - drug therapy Heart Failure - epidemiology High‐sensitivity troponin T Hospitalization Humans Male Middle Aged Natriuretic Peptide, Brain NT‐proBNP Peptide Fragments Sodium Sodium-Glucose Transporter 2 Inhibitors Sodium–glucose co‐transporter 2 inhibitors Symporters Type 2 diabetes mellitus |
| title | Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T22%3A02%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relationship%20between%20baseline%20cardiac%20biomarkers%20and%20cardiovascular%20death%20or%20hospitalization%20for%20heart%20failure%20with%20and%20without%20sodium%E2%80%93glucose%20co%E2%80%90transporter%202%20inhibitor%20therapy%20in%20DECLARE%E2%80%90TIMI%2058&rft.jtitle=European%20journal%20of%20heart%20failure&rft.au=Zelniker,%20Thomas%20A.&rft.date=2021-06&rft.volume=23&rft.issue=6&rft.spage=1026&rft.epage=1036&rft.pages=1026-1036&rft.issn=1388-9842&rft.eissn=1879-0844&rft_id=info:doi/10.1002/ejhf.2073&rft_dat=%3Cproquest_cross%3E2466772027%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2466772027&rft_id=info:pmid/33269486&rfr_iscdi=true |